StimCell Energetics Inc. (OTCQB:STME) has entered into an Advisory Services Agreement with Stonegate Capital Markets, Inc., appointing the Texas-based firm as a non-exclusive adviser for potential transactions involving the company’s assets, property, rights, debt or equity securities.
#Advisory agreement covers potential transactions
The agreement took effect on August 24, 2026. Stonegate will work on a best-efforts basis to identify and introduce prospective investors and strategic counterparties to StimCell Energetics.
Any proposed transaction must be mutually agreed by the parties, and all transactions remain subject to the company’s approval. The announcement does not state that a financing or other capital-market transaction has been completed.
#Fee tied to completed transactions
StimCell Energetics has agreed to pay Stonegate a success-based advisory fee for services connected with any completed transaction involving a Stonegate contact. The fee will be calculated as a percentage of Gross Proceeds and will be payable upon closing. The announcement does not specify the percentage.
#Contract period and possible offerings
The agreement has an initial three-month contract period. After that period, either party may end the arrangement by providing thirty (30) days’ written notice.
Unless the parties agree otherwise in writing, any securities offering linked to Stonegate’s capital-raising activities is expected to use Rule 506(c) of Regulation D under the Securities Act of 1933. StimCell Energetics remains responsible for Form D and applicable state blue-sky notice filings.
Further terms apply to the engagement beyond those set out here.
#Separate Stonegate arrangement
StimCell Energetics said the new engagement is separate from its previously announced advisory arrangement with Stonegate Capital Partners, Inc. That separate arrangement concerns research coverage and institutional investor outreach.
#Company focus and stated risks
StimCell Energetics describes its business as focused on the discovery, development and commercialisation of therapeutic and non-therapeutic products intended to enhance cellular function, promote general wellness and address health complications including aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. Its stated research priorities include eBalance® Technology and the eBalance® Home System.
The company’s announcement includes forward-looking statements and says they are subject to risks, uncertainties and assumptions. It states that actual results and future events could differ materially from those anticipated and that there can be no assurance that the statements will prove accurate.
The announcement also states that no stock exchange, securities commission or other regulatory body has reviewed or accepted responsibility for its adequacy or accuracy.
#Key Takeaways
- StimCell Energetics entered into a non-exclusive advisory agreement with Stonegate Capital Markets effective August 24, 2026.
- Stonegate will seek to identify and introduce potential investors and strategic counterparties for transactions that require StimCell’s approval.
- Stonegate’s fee would be success-based, calculated as a percentage of Gross Proceeds and payable upon closing of a completed transaction involving its contact.
- The agreement has an initial three-month term and may later be terminated by either party with thirty (30) days’ written notice.
- The engagement is separate from StimCell’s arrangement with Stonegate Capital Partners, Inc. for research coverage and institutional investor outreach.
Original source: Read original article